FIELD: medicine; immunology.
SUBSTANCE: invention can be used for induction of mucosal immunity to human papillomavirus (HPV). Composition contains a lactic acid bacterium containing on its surface a human papillomavirus (HPV) protein E7 derived polypeptide. Polypeptide derived from the E7 protein HPV is fused with the anchor protein cA derived from AcmA, with formation of a fused protein or is expressed from a nucleic acid sequence encoding an E7-derived HPV polypeptide associated with an anchor PrtP gene, where the E7 protein-derived HPV polypeptide is included in amount of 0.03 to 1.0 mcg per 1×108 lactic acid bacteria on bacterial surface.
EFFECT: use of the given invention enables to obtain an oral composition for HPV of an infectious disease and an HPV-associated tumor inducing mucosal immunity, increasing quantity of IFN-γ-producing cells.
7 cl, 3 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE COMPOSITION APPLICABLE IN HPV AND HEPATITIS VIRUS INFECTIONS, AND METHOD FOR PREPARING IT | 2009 |
|
RU2509570C2 |
| STABLE VECTOR OF CONSTITUTIVELY HIGH EXPRESSION FOR OBTAINING HPV VACCINE, AND RECOMBINANT LACTIC ACID BACTERIA TRANSFORMED BY THIS VECTOR | 2010 |
|
RU2492240C2 |
| VACCINES AGAINST HPV | 2012 |
|
RU2644201C2 |
| OPTIMISED EXPRESSION OF HPV 58 L1 IN YEAST | 2004 |
|
RU2370538C2 |
| COMPOSITION FOR TREATING CANCER ASSOCIATED WITH HPV INFECTION | 2017 |
|
RU2664466C1 |
| HPV CHIMERIC PARTICLE | 2012 |
|
RU2642287C2 |
| METHOD FOR TREATING INFECTION CAUSED WITH HUMAN PAPILLOMA VIRUS (HPV) | 2001 |
|
RU2282461C2 |
| MUCOSAL VACCINE FOR IMMUNE THERAPY OF DISEASES CAUSED BY HUMAN PAPILLOMA VIRUSES, AND RELATED THERAPY (VERSIONS) | 2008 |
|
RU2377305C1 |
| OPTIMISED EXPRESSION OF HPV 52 L1 IN YEAST | 2005 |
|
RU2373219C2 |
| VACCINE AGAINST HUMAN PAPILLOMA VIRUSES HPV16 AND HPV18 AND AT LEAST ONE MORE TYPE HPV, SELECTED FROM HPV 31,45 OR 52 | 2005 |
|
RU2420313C2 |
